Number of shares and votes in Calliditas Therapeutics
On December 30, 2022, Calliditas Therapeutics AB announced the issuance of 415,000 common shares related to its long-term incentive program 2019/2022. This issuance brings the total number of shares and votes to 59,572,587. The biopharma company, focusing on treatments for orphan diseases, has its lead product, Nefecon, granted accelerated FDA approval as TARPEYO® and conditional European authorization as Kinpeygo®. Calliditas is also advancing clinical trials for setanaxib, targeting primary biliary cholangitis and head and neck cancer.
- Total shares increased to 59,572,587, enhancing liquidity.
- Lead product Nefecon received accelerated FDA approval and conditional EU authorization.
- Ongoing clinical trials for setanaxib may expand treatment portfolio.
- None.
STOCKHOLM, Dec. 30, 2022 /PRNewswire/ -- During December, Calliditas Therapeutics AB (publ) has issued 415,000 common shares connected to the company's long term incentive program 2019/2022. Thus, as of December 30, 2022, the number of shares and votes in the company amounts to 59,572,587 shares and 59,572,587 votes.
For further information, please contact:
Mikael Widell, Investor relations
Tel.: +46 703 11 99 60, email: mikael.widell@calliditas.com
The information in the press release is such that Calliditas Therapeutics AB (publ) is required to disclose pursuant to the Swedish Financial Instruments Trading Act. The information was submitted for publication, through the agency of the contact persons set out above, at 08:00 CET on December 30, 2022.
About Calliditas
Calliditas Therapeutics is a commercial stage biopharma company based in Stockholm, Sweden focused on identifying, developing and commercializing novel treatments in orphan indications, with an initial focus on renal and hepatic diseases with significant unmet medical needs. Calliditas' lead product, developed under the name Nefecon, has been granted accelerated approval by the FDA under the trade name TARPEYO® and conditional marketing authorization by the European Commission under the trade name Kinpeygo®. Additionally, Calliditas is conducting a Phase 2b/3 clinical trial in primary biliary cholangitis and a Phase 2 proof-of-concept trial in head and neck cancer with its NOX inhibitor product candidate, setanaxib. Calliditas' common shares are listed on Nasdaq Stockholm (ticker: CALTX) and its American Depositary Shares are listed on the Nasdaq Global Select Market (ticker: CALT).
The following files are available for download:
Number of shares and votes December 2022 (Eng) |
View original content:https://www.prnewswire.com/news-releases/number-of-shares-and-votes-in-calliditas-therapeutics-301711322.html
SOURCE Calliditas Therapeutics
FAQ
What is the latest share count for Calliditas Therapeutics as of December 30, 2022?
What product has Calliditas Therapeutics received accelerated approval for?
What is the focus of Calliditas Therapeutics?
What are the ticker symbols for Calliditas Therapeutics?
What clinical trials are currently being conducted by Calliditas Therapeutics?
